Silence Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +131.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 3.9% of float.
- Analyst tilt is Hold.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 61.5% | Better than 76% |
| Operating margin | -16,056.0% | Better than 1% |
| Net margin | -15,851.9% | Better than 1% |
| Return on equity | -90.3% | Better than 6% |
| Return on invested capital | -92.8% | Better than 2% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 49.3% | Better than 100% |
| 6-month return | 219.5% | Better than 100% |
| 12-month return (ex latest month) | 211.7% | Better than 99% |
| Distance below 52-week high | 0.3% | Better than 99% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 8.7x | Better than 92% |
| Debt to assets | 0.1% | Better than 98% |
| Interest coverage | -1,478.7x | Better than 2% |
Analyst View F
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 0.0% | Better than 0% |
| Upside to average target | 1.0% | Better than 4% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 19.81
- Open
- 19.81
- Day range
- 19.80 - 19.83
- Avg price
- 19.81
- Volume
- 399.15K
- Turnover
- 7.91M
- Turnover ratei
- 0.80%
- Volume ratioi
- 0.49
- Amplitudei
- 0.15%
- 52-week rangei
- 4.19 - 19.87
Valuation
- P/Ei
- -10.48
- P/E (TTM)i
- -18.87
- P/Bi
- -5.73
- EPSi
- -1.89
- Book value / shi
- -3.46
- Net profit
- -117.56M
- Net assets
- -215.04M
Share structure
- Market cap
- 1.23B
- Float capi
- 993.90M
- Shares out
- 62.20M
- Float sharesi
- 50.17M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
0.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-107.31M net over the window
Short interest
- Shares short
- 2.42M
- % of floati
- 3.89%
- Days to coveri
- 1.00
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Silence Therapeutics (SLN)?
Silence Therapeutics last traded at 19.81. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Silence Therapeutics's market cap?
About 1.23B.
What is the P/E ratio of Silence Therapeutics?
The trailing twelve-month P/E is -18.87. The Valuation tab shows it against the stock's own five-year range.
Does Silence Therapeutics pay a dividend?
Silence Therapeutics does not currently pay a regular dividend.
Is Silence Therapeutics a buy according to analysts?
The consensus of 4 analysts is a Hold rating, with an average 12-month price target of 20.00, which implies 1.0% upside from the current price. This is not investment advice.
What is Silence Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Silence Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Silence Therapeutics discussion 0 comments